Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.

MLA

Loree, Jonathan M., et al. “Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 30, no. 15, Aug. 2024, pp. 3189–99. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-24-0268.

APA

Loree, J. M., Titmuss, E., Topham, J. T., Kennecke, H. F., Feilotter, H., Virk, S., Lee, Y. S., Banks, K., Quinn, K., Karsan, A., Renouf, D. J., Jonker, D. J., Tu, D., O’Callaghan, C. J., & Chen, E. X. (2024). Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 30(15), 3189–3199. https://doi.org/10.1158/1078-0432.CCR-24-0268

Chicago

Loree, Jonathan M, Emma Titmuss, James T Topham, Hagen F Kennecke, Harriet Feilotter, Shakeel Virk, Young S Lee, et al. 2024. “Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 30 (15): 3189–99. doi:10.1158/1078-0432.CCR-24-0268.